
COVID-19: Risk Assessment and Mitigation Strategies for the Collection of PRO Data through Clinical Sites – Lessons Learned

This webinar provides an update from sponsors and eCOA providers as they discuss lessons learned from managing clinical trials that originally planned for in-person collection of ePRO data through clinical sites. Due to public health concerns, many patients are either unable or unwilling to travel to sites for scheduled visits or sites have had to close. In March 2020, ePRO Consortium and PRO Consortium member representatives collaborated on risk assessment and mitigation strategies for clinical trials in response to COVID-19. This webinar discusses lessons learned, how the initial recommendations performed, and how sponsors and eCOA providers are applying these learnings to future trials.

■

[PDF version](#)

Moderator: Sonya Eremenco, MA (C-Path)

Presenters: Patricia (Trish) Delong, MS (Janssen Global Services, LLC); Gena Gough, MBA, PMP (Clinical Ink); Cindy Howry, MS (.assisTek); Paul O'Donohoe, MSc (Medidata Solutions); and, Megan Turner (GlaxoSmithKline)